GlaxoSmithKline plc (UK) (GB:GSK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GlaxoSmithKline plc reports that its Shingrix vaccine has proven to maintain high efficacy in preventing shingles in adults aged 50 and over for more than a decade. The final data from the phase III ZOSTER-049 trial showed a vaccine efficacy of 79.7% after six to 11 years, with no new safety concerns, bolstering confidence in long-term immunization strategies. This comes as a significant development given the risk shingles poses to adults as the immune system naturally declines with age.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
